Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14293238 | 0.90 | L3MBTL1 (0.39) | L3MBTL1MAPTHTTALDH1A1 | |
| SCHEMBL1208838 | 0.89 | ALDH1A1 (0.48) | MAPTPOLBMEN1KMT2AALDH1A1 | |
| SCHEMBL14292425 | 0.86 | KDM4E (0.38) | MAPTALDH1A1 | |
| SCHEMBL14292416 | 0.83 | RAB9A (0.41) | L3MBTL1MAPTHTTPOLBMEN1 | |
| SCHEMBL1207173 | 0.83 | ALDH1A1 (0.46) | L3MBTL1MAPTPOLBMEN1KMT2A | |
| SCHEMBL12894588 | 0.83 | THRB (0.41) | RXFP1THRBL3MBTL1FLT3MAPT | |
| SCHEMBL12895473 | 0.80 | MAPT (0.39) | RXFP1THRBMAPTPOLBMEN1 | |
| SCHEMBL12895684 | 0.80 | SLC8A1 (0.36) | RXFP1THRBFLT3MAPTPOLB | |
| SCHEMBL12895524 | 0.80 | MAPT (0.35) | RXFP1THRBMAPTPOLBMEN1 | |
| SCHEMBL12895374 | 0.79 | THRB (0.35) | RXFP1THRBFLT3MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | NYCOMED GMBH (DE) | 2011-02-24 | — | — | US | disclosed |
| WO-2008020045-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | 4SC AG (DE) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110044938-A1 | TETRAHYDROBENZOTHIOPHENE DERIVATIVES | BAX, BCL2, BAD | RXFP1 4173/4885THRB 489/4885KCNQ2 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.